Clinical trial • Phase I • Oncology
AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
Phase I trial of AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer. 347 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Estrogen receptor-positive HER2-negative advanced breast cancer
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 24-04-2024
- First CTIS Authorization Date
- 29-04-2024
Trial design
Phase I trial across 5 sites in Spain.
- Target Sample Size
- 347
Recruitment
- Planned Sample Size
- 347
- Recruitment Window Months
- 99
Geography
- Total Number Of Sites
- 5
- Total Number Of Participants
- 347
Spain
- Earliest CTIS Part Ii Submission Date
- 13-12-2023
- Latest Decision Or Authorization Date
- 12-03-2026
- Processing Time Days
- 820
- Number Of Sites
- 5
- Number Of Participants
- 173
Sites
- Site Name
- Hospital Clinic De Barcelona
- Department Name
- Medical Oncology
- Contact Person Name
- Ivan Victoria Ruiz
- Contact Person Email
- ivictori@recerca.clinic.cat
- Site Name
- Hospital Universitario Hm Sanchinarro
- Department Name
- Medical Oncology
- Contact Person Name
- Irene Moreno
- Contact Person Email
- irene.moreno@startmadrid.com
- Site Name
- University Hospital Virgen Del Rocio S.L.
- Department Name
- Medical Oncology
- Contact Person Name
- Manuel Ruiz Borrego
- Contact Person Email
- ruizsabater@gmail.com
- Site Name
- Hospital Universitari Vall D Hebron
- Department Name
- Medical Oncology
- Contact Person Name
- Mafalda Oliveira
- Contact Person Email
- moliveira@vhio.net
- Site Name
- Hospital Clinico Universitario De Valencia
- Department Name
- Medical Oncology
- Contact Person Name
- Begona Bermejo de las Heras
- Contact Person Email
- begobermejo@gmail.com
Sponsor
Primary sponsor
- Full Name
- Astrazeneca AB
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Sweden
Investigational products
- Investigational Product Name
- AZD9833
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.
- CAMIZESTRANT for Estrogen receptor-positive HER2-negative advanced breast cancer
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)